The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Defining the genetic evolution of epigenetic alterations in bladder cancer.
 
Timothy Nguyen Clinton
No Relationships to Disclose
 
Hannah Wise
No Relationships to Disclose
 
Nima Almassi
No Relationships to Disclose
 
Shweta S. Chavan
No Relationships to Disclose
 
Wenhuo Hu
No Relationships to Disclose
 
Sizhi Paul Gao
No Relationships to Disclose
 
Aphrothiti Hanrahan
No Relationships to Disclose
 
Shawn Dason
No Relationships to Disclose
 
Eugene J. Pietzak
No Relationships to Disclose
 
Maria Isabel Carlo
Consulting or Advisory Role - Pfizer
Other Relationship - Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Samuel Aaron Funt
Stock and Other Ownership Interests - Allogene Therapeutics; Hubble (I); Kite, a Gilead company; Kronos Bio (I); Neogene Therapeutics (I); Second Science; Urogen pharma (I); Vida Ventures (I)
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst)
Research Funding - AstraZeneca (Inst); Decibel Therapeutics (Inst); Genentech/Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb
 
Min Yuen Teo
Research Funding - Bristol-Myers Squibb; Clovis Oncology
 
Gopa Iyer
Consulting or Advisory Role - Bayer; Janssen; Mirati Therapeutics
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Mirati Therapeutics (Inst); Novartis (Inst)
 
Bernard H. Bochner
Honoraria - Genentech/Roche
Consulting or Advisory Role - Genentech/Roche; Olympus
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Clinical Care Options; ClinicalMind; Intellisphere; Medscape; Peerview; Research To Practice; UpToDate; Vindico
Consulting or Advisory Role - Adicet Bio; Agensys; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; GlaxoSmithKline; Inovio Pharmaceuticals; Janssen Oncology; Lilly; Merck; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Sensei Biotherapeutics; western oncolytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Seagen (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Merck; Novartis; Pfizer; Roche; Roche/Genentech; Urogen pharma
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech; Urogen pharma
 
Maria E. Arcila
Honoraria - Biocartis; Invivoscribe
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Invivoscribe; Raindance Technologies
 
Hikmat Al-Ahmadie
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono
 
Barry S. Taylor
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Genentech
 
David B. Solit
Stock and Other Ownership Interests - Loxo
Consulting or Advisory Role - Illumina; Intezyne Technologies; Lilly; Loxo; Pfizer; Vividion Therapeutics
Travel, Accommodations, Expenses - Merck KGaA